Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 15/20 | 0.45 |
| ▸ | JAK1 | P23458 | 15/20 | 0.45 |
| ▸ | TYK2 | P29597 | 15/20 | 0.45 |
| ▸ | JAK3 | P52333 | 15/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5982464 | 0.85 | HCAR3 (0.55) | HSD17B10HCAR3 | |
| SCHEMBL5983851 | 0.85 | FGFR1 (0.46) | ALDH1A1SMN1; SMN2HSD17B10FGFR1HCAR3 | |
| SCHEMBL5983097 | 0.81 | HPGD (0.42) | ALDH1A1SMN1; SMN2HCAR3 | |
| SCHEMBL5982863 | 0.81 | THRB (0.46) | SMN1; SMN2KMT2A | |
| SCHEMBL8032996 | 0.75 | HPGD (0.44) | KDM4EALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL29750942 | 0.73 | KDM4E (0.50) | KDM4EBRD4ALDH1A1BRPF1SMN1; SMN2 | |
| SCHEMBL1299105 | 0.72 | FGFR1 (0.60) | KDM4EBRD4ALDH1A1BRPF1SMN1; SMN2 | |
| SCHEMBL21409085 | 0.72 | HCAR3 (0.73) | KDM4EBRD4ALDH1A1BRPF1SMN1; SMN2 | |
| SCHEMBL29751005 | 0.72 | HCAR3 (0.73) | KDM4EBRD4ALDH1A1BRPF1SMN1; SMN2 | |
| SCHEMBL4220293 | 0.72 | HCAR3 (0.47) | KDM4EALDH1A1HSD17B10KMT2AFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1634888-A2 | Synthesis of 2'-deoxy-L-nucleosides | Pharmasset Limited (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1600451-A2 | Synthesis of 2'-deoxy-l-nucleosides | Pharmasset Limited (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20050090660-A1 | 2'-deoxy-L-nucleosides | PHARMASSET, INC. | 2005-04-28 | — | — | US | disclosed |
| EP-1232166-A2 | SYNTHESIS OF 2'-DEOXY-L-NUCLEOSIDES | Pharmasset Limited (US) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001034618-A2 | SYNTHESIS OF 2'-DEOXY-L-NUCLEOSIDES | PHARMASSET LIMITED (US) | 2001-05-17 | — | — | WO | disclosed |
| US-5614519-A | (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists | KARL THOMAE GMBH (DE) | 1997-03-25 | — | — | US | disclosed |
| US-5602127-A | ADMINISTERING TO TREAT HYPERTENSION | KARL THOMAE GMBH (DE) | 1997-02-11 | — | — | US | disclosed |
| US-5594003-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-14 | — | — | US | disclosed |
| US-5591762-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-07 | — | — | US | disclosed |
| US-5565469-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1996-10-15 | — | — | US | disclosed |
| CN-1113235-A | Benzimidazoles, pharmaceutical compositions containing these compounds and processes for preparing them | THOMAE GMBH DR K (DE) | 1995-12-13 | — | — | CN | disclosed |
| EP-0682021-A1 | Benzimidazoles, medicines containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1995-11-15 | — | — | EP | disclosed |
| EP-0502314-A1 | Benzimidazol, medicaments containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1992-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090660-A1 | 2'-deoxy-L-nucleosides | CCNH, ADAR, NSUN2 | KDM4E 2504/4885BRD4 3760/4885ALDH1A1 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.